Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 15 Products per page

Tygacil
Read More
Tygacil (tigecycline; Pfizer) is the first of the glycylcycline class of antimicrobial agents. It targets and binds to the 30S subunit of the bacterial ribosomes.
June 19, 2015
Find out more
2019 Biomedtracker / Datamonitor Healthcare Post-ASCO Report

$2,995.00

The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, IL from May 31st through June 4th, 2019. This year’s conference was highly varied, with key data presented for drugs in numerous different classes and indications.

June 13, 2019
Find out more
Market Spotlight: Sarcoma

$1,318.00

This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 21, 2022
Find out more
Biopharma Quarterly Dealmaking Statistics, Q3 2016

$499.00

A look at biopharma financing, M&A and alliance activity July–September 2016, based on data from Strategic Transactions.
November 18, 2016
Find out more
Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market

$4,750.00

Symptomatic benign prostatic hyperplasia (BPH) and prostatitis affect more than 100 million men worldwide, lowering quality of life with painful symptoms that can be difficult to manage.
April 20, 2017
Find out more
MenQuadfi
Read More
Sanofi’s MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) is a second-generation active polyvalent conjugate vaccine against group A, C, Y, and W meningococcal infection. It is presented as a sterile solution for injection containing Neisseria meningitidis capsular polysaccharide antigens individually conjugated to tetanus toxoid protein.
September 3, 2019
Find out more
Alzheimer’s Disease KOL Interview – US, South

$599.00

This interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. Also discussed are treatment trends and current unmet needs.
January 28, 2019
Find out more
Xofigo
Read More
Xofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of increased bone metabolism, which are associated with bone metastases.
January 18, 2018
Find out more
France, Disease Incidence and Prevalence

$4,850.00

As the aging population in Europe increases and the average life span lengthens, the incidence and prevalence of many major diseases/disorders are expected to increase accordingly and significantly impact the European healthcare industry.

September 22, 2016
Find out more
Company Analysis: Sanofi

$3,000.00

PharmaVitae explores Sanofi’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
Semaglutide (Injectable)
Read More
Injectable semaglutide (Novo Nordisk) is a once-weekly glucagon-like peptide-1 (GLP-1) agonist currently seeking approval for the treatment of type 2 diabetes.
June 23, 2016
Find out more
Tafinlar
Read More
Tafinlar (dabrafenib; Novartis) is an adenosine triphosphate-competitive BRAF inhibitor with more than 100-fold selectivity for mutated BRAF over wild-type.
August 30, 2018
Find out more
Ulcerative Colitis (UC) KOL Interview – UK

$599.00

A UK expert in the ulcerative colitis (UC) field dives into the treatment algorithm, critical unmet needs, and pipeline drugs, such as the Janus kinase inhibitors and sphingosine 1-phosphate (S1P) modulators.
March 1, 2021
Find out more
Copiktra
Read More
Copiktra (duvelisib; Verastem/Yakult Honsha) is a highly selective small molecule inhibitor of the p110-delta and p110-gamma isoforms of the phosphoinositide 3-kinase (PI3K) enzyme.
January 31, 2019
Find out more
NASH KOL Insight Interview #1

$599.00

The prevalence data would suggest that in the US population about 30% of our population has fatty liver or NAFLD and of those 25% may have NASH and of those patients with NASH 25% percent may have fibrosis and progress to cirrhosis. It’s almost a pyramid effect, there may be 80 million Americans walking around with NAFLD, but to climb up to the top of the pyramid and develop cirrhosis would be about 5% of that total population, but that’s still significant because that would mean that the prevalence of cirrhosis [due to NASH] will exceed that of hepatitis C-related cirrhosis ten-fold
February 20, 2014
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *